Revenue
2009
2010
2011
2012
2013
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
InspireMD, Inc. (NSPR)
Price$0.8532Cached quote
Net income
2009
2010
2011
2012
2013
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 · Dec 31 | 2013 · Jun 30 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.0M | $7.0M | $6.2M | $5.2M | $4.5M | $2.5M | $3.7M | $3.6M | $2.8M | $1.9M | $2.3M | $2.8M | $3.1M | $4.9M | $5.3M | $6.0M | $4.9M | $3.4M |
| Gross profit | $2.6M | $1.5M | $1.8M | $1.1M | $754,000 | $83,000 | $756,000 | $995,000 | $585,000 | $102,000 | −$296,000 | $784,000 | $1.7M | $2.6M | $2.5M | $3.0M | $2.3M | $1.1M |
| Gross margin | 29.50% | 21.49% | 29.12% | 21.60% | 16.77% | 3.34% | 20.32% | 27.63% | 21.19% | 5.39% | −12.81% | 27.82% | 53.56% | 53.15% | 46.74% | 49.85% | 45.52% | 32.83% |
| Research & development | $15.0M | $13.6M | $8.0M | $7.8M | $5.2M | $2.2M | $3.0M | $1.5M | $1.3M | $1.3M | $3.6M | $8.7M | $3.3M | $4.2M | $4.0M | $2.5M | $1.3M | $1.3M |
| Operating expenses | $52.3M | $35.0M | $22.9M | $19.8M | $15.5M | $10.5M | $10.6M | $8.6M | $8.8M | $7.8M | $14.2M | $24.5M | $10.5M | $17.7M | $20.0M | $16.7M | $5.5M | $3.8M |
| Operating income | −$49.6M | −$33.5M | −$21.1M | −$18.7M | −$14.7M | −$10.4M | −$9.8M | −$7.6M | −$8.2M | −$7.6M | −$14.5M | −$23.7M | −$8.8M | −$15.1M | −$17.5M | −$13.7M | −$3.2M | −$2.7M |
| Operating margin | −552.56% | −478.00% | −340.74% | −361.88% | −327.39% | −417.71% | −263.80% | −211.36% | −298.15% | −403.80% | −627.06% | −840.95% | −284.28% | −309.32% | −328.01% | −228.66% | −65.04% | −79.65% |
| EBITDA | $426.4M | $246.5M | $210.9M | $169.3M | −$14.6M | −$10.2M | −$9.7M | −$7.5M | −$8.1M | −$7.5M | −$14.3M | −$23.4M | −$8.7M | −$14.9M | −$17.4M | −$13.6M | −$3.1M | −$2.6M |
| EBITDA margin | 4,748.70% | 3,516.86% | 3,398.18% | 3,273.78% | −323.80% | −411.63% | −259.55% | −207.50% | −292.61% | −396.30% | −620.48% | −831.62% | −280.74% | −305.05% | −325.76% | −227.18% | −63.20% | −77.04% |
| Net income | −$48.8M | −$32.0M | −$19.9M | −$18.5M | −$14.9M | −$10.5M | −$10.0M | −$7.2M | −$8.4M | −$8.5M | −$15.6M | −$25.1M | −$9.3M | −$29.3M | −$17.6M | −$14.7M | −$3.4M | −$2.7M |
| Net profit margin | −543.33% | −456.63% | −320.97% | −357.59% | −331.88% | −424.31% | −269.82% | −201.06% | −305.61% | −446.73% | −674.68% | −890.53% | −300.68% | −600.41% | −328.98% | −244.25% | −69.10% | −79.86% |
| Basic EPSper basic share | -$0.76 | -$0.76 | -$0.82 | -$2.35 | -$2.03 | -$6.97 | -$72.00 | -$250.05 | -$524.70 | -$3,115.80 | -$837.75 | -$2,658.75 | -$1,012.50 | -$5,212.50 | -$3,900.00 | -$3,600.00 | -$1,050.00 | -$900.00 |
| Diluted EPSper diluted share | -$0.76 | -$0.76 | -$0.82 | -$2.35 | -$2.03 | -$6.97 | -$72.00 | -$250.05 | -$524.70 | -$3,115.80 | -$837.75 | -$2,658.75 | -$1,012.50 | -$5,212.50 | -$3,900.00 | -$3,600.00 | -$1,050.00 | -$900.00 |
Owners
Reported shareholders
14.39%of listed shares
Nantahala Capital Management, LLC6.75M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Nantahala Capital Management, LLC | 14.39%6.75M shares |
Rosalind Advisors, Inc. | 8.32%3.91M shares |
Aberdeen Group plc | 7.88%3.7M shares |
Slosman Marvin | ≈7.58%3.56M shares |
ORBIMED ADVISORS LLC | 6.68%3.13M shares |
Parkman Healthcare Partners LLC | 5.15%2.42M shares |
MARSHALL WACE, LLP | 3.96%1.86M shares |
Shore Craig | ≈2.37%1.11M shares |
Stuka Paul | ≈2.33%1.09M shares |
Gleason Shane Thomas | ≈2.25%1.05M shares |
Soleus Capital Management, L.P. | 2.23%1.05M shares |
Tommasoli Andrea | ≈2.03%954.39K shares |
ROUBIN GARY S | ≈1.78%834.48K shares |
Lawless Michael A | ≈1.47%691.7K shares |
BERMAN MICHAEL | ≈1.27%597.58K shares |
Kester Thomas J | ≈0.98%458.57K shares |
PURA VIDA INVESTMENTS, LLC | 0.96%450.52K shares |
INGALLS & SNYDER LLC | 0.79%368.8K shares |
Verta Patrick | ≈0.66%311.53K shares |
Arnold Kathryn | ≈0.65%303.09K shares |
Percentages use 46.92M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 27, 2026Form 4 | Stuka PaulDirector | BuyCommon Stock | 20.0K | $0.88 | $17.6K | 667.9K |
| May 19, 2026Form 4 | Gleason Shane ThomasChief Commercial Officer | SellCommon Stock | 22.8K | $1.01 | $23.0K | 1.05M |
| May 14, 2026Form 4 | Stuka PaulDirector | BuyCommon Stock | 5.0K | $1.15 | $5.8K | 647.9K |
| May 13, 2026Form 4 | Stuka PaulDirector | BuyCommon Stock | 10.0K | $1.16 | $11.6K | 642.9K |
| May 12, 2026Form 4 | Slosman MarvinCEO and President | BuyCommon Stock | 21.0K | $1.20 | $25.2K | 3.56M |